Status:
COMPLETED
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18-130 years
Phase:
PHASE2
Brief Summary
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
Eligibility Criteria
Inclusion
- Locally advanced or hereditary medullary thyroid cancer
- Signed informed consent
- One or more measurable lesions
Exclusion
- Brain metastases or spinal cord compression
- Specific laboratory ranges
- Specific heart problems
- Prior chemotherapy and/or radiation therapy
- Participation in other trials within 30 days
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 19 2017
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00098345
Start Date
November 1 2004
End Date
April 19 2017
Last Update
May 7 2018
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
San Francisco, California, United States
2
Research Site
New Haven, Connecticut, United States
3
Research Site
New York, New York, United States
4
Research Site
Durham, North Carolina, United States